Peter Zerhouni has been named as the new chief executive of InDex Pharmaceuticals AB to succeed Jesper Wiklund who is leaving the company in order to direct a life science investment company. Mr Zerhouni, who will assume the CEO post on 1 April, comes from Diamyd Medical AB where he was chief executive and head of business development. He has previously worked as a banker at the ING Bank offices in both Brussels and Amsterdam. Mr Zerhouni has both biology and MBA degrees from the University of Lund in Sweden and the University of California at Berkeley in the US.
InDex announced the appointment on 5 February 2015.
Copyright 2015 Evernow Publishing Ltd